Related Experiment Video
Updated: May 22, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls
Basak Oven Ustaalioglu1, Ahmet Bilici, Serif Ercan
1Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. basakoven@yahoo.com
Background:
M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced nonsmall- cell lung cancer (NSCLC) compared with those in a healthy group.
Material And Methods:
Thirty-two patients with advanced NSCLC and thirty-two healthy people were included in the study. Serum M30 and M65 values were measured by quantitative ELISA method. The best cut-off value for serum M65 was calculated by ROC analysis and then univariate analysis was performed to determine the importance of M65 value in predicting progression-free survival (PFS).
Results:
There were no differences between mean serum M30 values between patients and controls (445.44±536.17 vs. 340.56±345.07, p=1). The mean serum M65 values were found to be significantly higher in patients than in healthy controls (1421.30±1662.59 vs. 648.85±341.17, p<0.001). The best cut-off value for serum M65 predicting PFS was 1311.64 U/l (AUC 0.58, sensitivity and specificity were 45.5% and 85.7% respectively). The patients with serum M65 values ≥1311.64 U/l had worse PFS than patients with serum M65 values <1311.64 U/l, p=0.01). There was no correlation between serum M30 value and PFS in the patient group (p=0.4).
Conclusions:
Our results indicated that serum M65 values elevated in advanced NSCLC compared to a healthy control group and elevated serum M65 level can predict PFS in patients.
Insights
Serum M65 levels are elevated in advanced non-small cell lung cancer (NSCLC) patients and can predict progression-free survival (PFS). M30 levels showed no significant difference or correlation with PFS in NSCLC.
Area of Science:
- Oncology
- Biomarkers
- Cancer Research
Background:
- M30 and M65 are cytokeratin 18 derivatives released during epithelial cell death.
- These markers are utilized for prognosis and chemotherapy response assessment in various cancers.
- This study investigates serum M30 and M65 in advanced non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To compare serum M30 and M65 levels in advanced NSCLC patients versus healthy individuals.
- To determine if serum M65 can predict progression-free survival (PFS) in NSCLC patients.
Main Methods:
- Quantitative ELISA was used to measure serum M30 and M65 in 32 advanced NSCLC patients and 32 healthy controls.
- ROC analysis identified the optimal cut-off value for serum M65 in predicting PFS.
- Univariate analysis assessed the predictive value of M65 for PFS.
Main Results:
- Mean serum M30 levels did not differ significantly between NSCLC patients and controls (p=1).
- Mean serum M65 levels were significantly higher in NSCLC patients than in controls (p<0.001).
- An M65 cut-off of 1311.64 U/l predicted worse PFS (p=0.01), while M30 showed no correlation with PFS.
Conclusions:
- Elevated serum M65 levels are characteristic of advanced NSCLC compared to healthy controls.
- Serum M65 is a potential predictor of progression-free survival in advanced NSCLC patients.
- Serum M30 levels do not appear to be a significant prognostic marker for PFS in this cohort.